Cited 45 times in
Neutralization of Ocular Surface TNF-α Reduces Ocular Surface and Lacrimal Gland Inflammation Induced by In Vivo Dry Eye
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 노혜미 | - |
dc.contributor.author | 변유정 | - |
dc.contributor.author | 이형근 | - |
dc.contributor.author | 정은애 | - |
dc.contributor.author | 최웅락 | - |
dc.contributor.author | 지용우 | - |
dc.date.accessioned | 2014-12-18T09:47:59Z | - |
dc.date.available | 2014-12-18T09:47:59Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0146-0404 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/88852 | - |
dc.description.abstract | PURPOSE: The purpose of this study was to investigate the effectiveness of tumor necrosis factor (TNF)-α blocker for treatment of dry eye (DE)-induced inflammation and determine a more effective method to suppress lacrimal gland inflammation. Efficacy of topical versus systemic administration of TNF-α blockers was determined using a murine dry eye (DE) model. METHODS: The TNF-α blocker HL036 was developed by modification of the TNF receptor I. Protein purity, binding affinity, and clearance of TNF-α was compared with etanercept. Using DE-induced C57BL/6 mice, corneal erosion and goblet cell counts were measured after subcutaneous or topical treatment with etanercept or HL036. Inflammatory cytokines in cornea and lacrimal glands were determined by quantitative RT-PCR and ELISA. RESULTS: HL036 showed TNF-α binding affinity comparable to etanercept, as measured by surface plasmon resonance. HL036 concentration was significantly higher in cornea and anterior segment than etanercept and effectively eliminated TNF-α on ocular surfaces. Etanercept was preferentially concentrated in the posterior segment. Corneal erosion and goblet cell counts were improved only with topically applied etanercept and HL036. Ocular surface IFN-γ, IL-6, and IL-21 were significantly decreased by topical HL036. DE-induced lacrimal gland IFN-γ and IL-6 expression was effectively suppressed by topical etanercept and HL036. CONCLUSIONS: Topical TNF-α blockers effectively suppressed lacrimal gland and corneal inflammation by suppressing IFN-γ, IL-21, and IL-6. Differences in TNF-α affinity, clearance, and local concentration of blockers may account for the anti-inflammatory effects in different ocular regions. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Cell Count | - |
dc.subject.MESH | Cornea/metabolism | - |
dc.subject.MESH | Cytokines/metabolism | - |
dc.subject.MESH | Dacryocystitis/drug therapy* | - |
dc.subject.MESH | Dacryocystitis/etiology | - |
dc.subject.MESH | Dacryocystitis/metabolism | - |
dc.subject.MESH | Disease Models, Animal* | - |
dc.subject.MESH | Enzyme-Linked Immunosorbent Assay | - |
dc.subject.MESH | Etanercept | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Goblet Cells/pathology | - |
dc.subject.MESH | Immunoglobulin G/pharmacology | - |
dc.subject.MESH | Keratitis/drug therapy* | - |
dc.subject.MESH | Keratitis/etiology | - |
dc.subject.MESH | Keratitis/metabolism | - |
dc.subject.MESH | Keratoconjunctivitis Sicca/complications* | - |
dc.subject.MESH | Lacrimal Apparatus/metabolism | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Mice, Inbred C57BL | - |
dc.subject.MESH | Real-Time Polymerase Chain Reaction | - |
dc.subject.MESH | Receptors, Tumor Necrosis Factor | - |
dc.subject.MESH | Receptors, Tumor Necrosis Factor, Type I/pharmacology* | - |
dc.subject.MESH | Tumor Necrosis Factor-alpha/antagonists & inhibitors* | - |
dc.title | Neutralization of Ocular Surface TNF-α Reduces Ocular Surface and Lacrimal Gland Inflammation Induced by In Vivo Dry Eye | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Life Science (의생명과학부) | - |
dc.contributor.googleauthor | Yong Woo Ji | - |
dc.contributor.googleauthor | Yu Jeong Byun | - |
dc.contributor.googleauthor | Wungrak Choi | - |
dc.contributor.googleauthor | Eunae Jeong | - |
dc.contributor.googleauthor | Jin Sun Kim | - |
dc.contributor.googleauthor | Haemi Noh | - |
dc.contributor.googleauthor | Eun Sun Kim | - |
dc.contributor.googleauthor | Yun Jung Song | - |
dc.contributor.googleauthor | Seung Kook Park | - |
dc.contributor.googleauthor | Hyung Keun Lee | - |
dc.identifier.doi | 10.1167/iovs.12-11515 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01304 | - |
dc.contributor.localId | A01854 | - |
dc.contributor.localId | A03303 | - |
dc.contributor.localId | A03687 | - |
dc.contributor.localId | A04123 | - |
dc.relation.journalcode | J01187 | - |
dc.identifier.eissn | 1552-5783 | - |
dc.identifier.pmid | 24052636 | - |
dc.identifier.url | http://www.iovs.org/content/54/12/7557.long | - |
dc.subject.keyword | cytokines | - |
dc.subject.keyword | dry eye | - |
dc.subject.keyword | lacrimal gland | - |
dc.subject.keyword | tumor necrosis factor‐α | - |
dc.contributor.alternativeName | Noh, Hae Mi | - |
dc.contributor.alternativeName | Byun, Yu Jeong | - |
dc.contributor.alternativeName | Lee, Hyung Keun | - |
dc.contributor.alternativeName | Jeong, Eun Ae | - |
dc.contributor.alternativeName | Choi, Wung Rak | - |
dc.contributor.affiliatedAuthor | Noh, Hae Mi | - |
dc.contributor.affiliatedAuthor | Byun, Yu Jeong | - |
dc.contributor.affiliatedAuthor | Lee, Hyung Keun | - |
dc.contributor.affiliatedAuthor | Jeong, Eun Ae | - |
dc.contributor.affiliatedAuthor | Choi, Wung Rak | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 54 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 7557 | - |
dc.citation.endPage | 7566 | - |
dc.identifier.bibliographicCitation | INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, Vol.54(12) : 7557-7566, 2013 | - |
dc.identifier.rimsid | 33666 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.